32

BrainStorm

January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

61
April 16, 2024 | 12:53

Dr. Brent Forester – The Complexity of Dementia Care and the Importance of a Holistic Approach (part 2)

Join us for part 2 of BrainStorm’s interview with Dr. Brent Forester, Chairman of the Department of Psychiatry, and Director of Behavioral Health at Tufts Medical Center.
LISTEN NOW
60
April 2, 2024 | 16:29

Dr. Brent Forester – The Complexity of Dementia Care and the Importance of a Holistic Approach (part 1)

If you're facing the challenge of caring for a parent with dementia, you are not alone. In this episode of BrainStorm Brent Forester, MD, MSc, Psychiatrist in Chief, Chairman of the Department of Psychiatry, and Director of Behavioral Health at Tufts Medical Center, discussed the complexity of dementia care and the importance of a holistic approach with host Meryl Comer.
LISTEN NOW
59
March 19, 2024 | 13:08

Pierre N. Tariot, PhD – Neuropsychiatric Symptoms of Alzheimer’s and Dementia

Join us for part 2 of BrainStorm’s interview with Dr.

LISTEN NOW